Verastem, Inc. (VSTM)

NCM – Real vaqt narxi. Valyuta: USD

4.63

-0.25 (-5.12%)

Yopilishda: May 12, 2026, 4:00 PM EDT

4.68

+0.05 (1.08%)

Bozor oldidan: May 13, 2026, 6:47 AM EDT

12.05.2026

Verastem Oncology to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in New York City: HCW 4th Annual BioConnect Investor Conference: Tuesday, May 19, 2026, 4:00-4:30 pm ET RBC Global Healthcare Conference: Wednesday, May 20, 2026, 9:30-9:55 am ET A live webcast of the fire.

09.05.2026

Verastem Q1 Earnings Call Highlights

Verastem NASDAQ: VSTM reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade serous ovarian cancer continued to grow despite seasonal headwinds and some early commercial execution challenges.

08.05.2026

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed to support patients living with low-grade serous ovarian cancer (LGSOC), a rare and distinct form of ovarian cancer, along with their caregivers and advocates. Available at www.LGSOCAwarenessDay.org, the guide launches in conjunction with World Ovarian Cancer Day, a global effort to raise awareness.

08.05.2026

Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript

08.05.2026

Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates

Verastem (VSTM) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.96 per share a year ago.

07.05.2026

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent business progress. “As we mark the one-year anniversary of the FDA-approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, I am incredibly proud of the progress we have made to delive.

30.04.2026

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) campaign for AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets), the first and only treatment specifically approved by the U.S. Food and Drug Administration (FDA) for adult patients with KRAS-mutated recurrent.

Videolar

No Data

There is no data to display

Press-relizlar

08.05.2026

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

07.05.2026

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent business progress. “As we mark the one-year anniversary of the FDA-approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, I am incredibly proud of the progress we have made to delive.

30.04.2026

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) campaign for AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets), the first and only treatment specifically approved by the U.S. Food and Drug Administration (FDA) for adult patients with KRAS-mutated recurrent.

10.04.2026

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced two-year median follow-up data from the Phase 2 RAMP 201 clinical trial that evaluated AVMAPKI® FAKZYNJA® combination therapy (avutometinib capsules; defactinib tablets) in patients with recurrent low-grade serous ovarian cancer (LGSOC) will be presented today during an oral plenary session at the Society o.

Verastem, Inc. (VSTM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Verastem, Inc. (VSTM)

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Q1 Earnings Call Highlights

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Videolar

No Data

Press-relizlar

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Q1 Earnings Call Highlights

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Videolar

No Data

Press-relizlar

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers

Search stocks

Verastem, Inc. (VSTM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Verastem, Inc. (VSTM)

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Q1 Earnings Call Highlights

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Videolar

No Data

Press-relizlar

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Q1 Earnings Call Highlights

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Videolar

No Data

Press-relizlar

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers